These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16854751)

  • 1. Critical factors determining the potency of topical corticosteroids.
    Kirkland R; Pearce DJ; Balkrishnan R; Feldman SR
    J Dermatolog Treat; 2006; 17(3):133-5. PubMed ID: 16854751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of the vasoconstriction assay and clinical activity in psoriasis.
    Cornell RC; Stoughton RB
    Arch Dermatol; 1985 Jan; 121(1):63-7. PubMed ID: 3881088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An assessment of the relationship between vasoconstrictor assay findings, clinical efficacy and skin thinning effects of a variety of undiluted and diluted corticosteroid preparations.
    Gibson JR; Kirsch JM; Darley CR; Harvey SG; Burke CA; Hanson ME
    Br J Dermatol; 1984 Jul; 111 Suppl 27():204-12. PubMed ID: 6378245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are ointments better than other vehicles for corticosteroid treatment of psoriasis?
    Zivkovich AH; Feldman SR
    J Drugs Dermatol; 2009 Jun; 8(6):570-2. PubMed ID: 19537382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics and dermatopharmacokinetics of betamethasone 17-valerate: assessment of topical bioavailability.
    Wiedersberg S; Naik A; Leopold CS; Guy RH
    Br J Dermatol; 2009 Mar; 160(3):676-86. PubMed ID: 18782322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.
    Borelli C; Gassmueller J; Fluhr JW; Nietsch KH; Schinzel S; Korting HC
    Skin Pharmacol Physiol; 2008; 21(3):181-7. PubMed ID: 18523415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class I topical corticosteroid use by psoriasis patients in an academic practice.
    Pearce DJ; Spencer L; Hu J; Balkrishnan R; Fleischer AB; Feldman SR
    J Dermatolog Treat; 2004 Jul; 15(4):235-8. PubMed ID: 15764038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Topical corticosteroids and corticosteroid sparing therapy in psoriasis management].
    Sukarovska BG; Lipozencić J; Vrzogić P
    Acta Med Croatica; 2007 Sep; 61(4):375-81. PubMed ID: 18044472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.
    Görne RC; Greif C; Metzner U; Wigger-Alberti W; Elsner P
    Skin Pharmacol Physiol; 2007; 20(3):133-40. PubMed ID: 17191036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reflectance spectrophotometric quantification of skin colour changes induced by topical corticosteroid preparations.
    Feather JW; Ryatt KS; Dawson JB; Cotterill JA; Barker DJ; Ellis DJ
    Br J Dermatol; 1982 Apr; 106(4):437-43. PubMed ID: 7073967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity of fluocinonide on diseases and healthy skin in comparison with other topical corticosteroids.
    Kalkoff KW
    Acta Derm Venereol Suppl (Stockh); 1971 May; 52(67):51-6. PubMed ID: 5291633
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
    Lee CS; Koo J
    J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approaching psoriasis differently: patient-physician relationships, patient education and choosing the right topical vehicle.
    Feldman SR
    J Drugs Dermatol; 2010 Aug; 9(8):908-11. PubMed ID: 20684140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The skin-blanching assay.
    Smit P; Neumann HA; Thio HB
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1197-202. PubMed ID: 22303935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cushing's syndrome induced by misuse of moderate- to high-potency topical corticosteroids.
    Coureau B; Bussières JF; Tremblay S
    Ann Pharmacother; 2008 Dec; 42(12):1903-7. PubMed ID: 19017822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The psoriasis plaque test and topical corticosteroids: evaluation by computerized laser profilometry.
    Wolff HH; Kreusch JF; Wilhelm KP; Klaus S
    Curr Probl Dermatol; 1993; 21():107-13. PubMed ID: 8299362
    [No Abstract]   [Full Text] [Related]  

  • 17. A Randomized, Double-Blind, Placebo-Controlled Study of the Vasoconstrictor Potency of Topical 0.25% Desoximetasone Spray: A High to Super High Range of Potency (Class I to Class II) Corticosteroid Formulation.
    Oussedik E; Saleem MD; Feldman SR
    J Drugs Dermatol; 2017 Oct; 16(10):972-975. PubMed ID: 29036250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitriol 3 microg/g ointment: an effective and safe addition to the armamentarium in topical psoriasis therapy.
    Abramovits W
    J Drugs Dermatol; 2009 Aug; 8(8 Suppl):s17-22. PubMed ID: 19702032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A reappraisal of topical steroid potency.
    Hepburn DJ; Aeling JL; Weston WL
    Pediatr Dermatol; 1996; 13(3):239-45. PubMed ID: 8806127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical corticosteroids: a review of properties and principles in therapeutic use.
    Chaffman MO
    Nurse Pract Forum; 1999 Jun; 10(2):95-105. PubMed ID: 10542586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.